The FDA has approved Bydureon Pen (exenatide extended-release for injectable suspension; Bristol-Myers Squibb and AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in adults ...
AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The ...
AstraZeneca has received regulatory approval for a single-use pen injector to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence rates and a huge unmet ...
US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...
AstraZeneca announced the availability of Bydureon (exenatide extended-release for injectable suspension) Pen in pharmacies across the country. Bydureon is indicated as an adjunct to diet and exercise ...
WILMINGTON, Del. -- AstraZeneca has received regulatory approval for a single-use pen injector designed to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence ...
The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...
WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results